Company intelligence / Profile preview

InBio

Charlottesville, Virginia, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

InBio offers an extensive portfolio of validated diagnostic products (including multiparameter allergen assays and purified allergen proteins) widely adopted in clinical and research settings, with prominent scientific leadership in allergen characterization and environmental measurement technology. The company is pioneering CRISPR-based gene editing for cat allergy and new mass spectrometry-based allergen detection for food.

Therapeutic areas: ImmunologyPulmonology
Modalities: BiologicMonoclonal antibodyRecombinant proteinPurified natural protein
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

InBio CRISPR Fel d 1 gene editing

Preclinical

Partnerships

Collaborations with academic institutionsallergy diagnostics manufacturersglobal distributors including European regulatory agencies for assay validation

Beyond the preview

Go deeper on InBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InBio.

Explore the full profile